HK1063334A1 - Compositions and methods useful for hcv infection - Google Patents

Compositions and methods useful for hcv infection

Info

Publication number
HK1063334A1
HK1063334A1 HK04105318A HK04105318A HK1063334A1 HK 1063334 A1 HK1063334 A1 HK 1063334A1 HK 04105318 A HK04105318 A HK 04105318A HK 04105318 A HK04105318 A HK 04105318A HK 1063334 A1 HK1063334 A1 HK 1063334A1
Authority
HK
Hong Kong
Prior art keywords
compositions
hcv
methods
hcv infection
methods useful
Prior art date
Application number
HK04105318A
Other languages
English (en)
Inventor
Ann Kwong
Randal Byrn
Lola M Reid
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of HK1063334A1 publication Critical patent/HK1063334A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/18—Liver cell growth factor (LCGF, Gly-His-Lys)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/375—Thyroid stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Semiconductor Lasers (AREA)
HK04105318A 2001-03-27 2004-07-20 Compositions and methods useful for hcv infection HK1063334A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27917401P 2001-03-27 2001-03-27
PCT/US2002/009685 WO2002077206A1 (en) 2001-03-27 2002-03-27 Compositiona and methods useful for hcv infection

Publications (1)

Publication Number Publication Date
HK1063334A1 true HK1063334A1 (en) 2004-12-24

Family

ID=23067944

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04105318A HK1063334A1 (en) 2001-03-27 2004-07-20 Compositions and methods useful for hcv infection

Country Status (15)

Country Link
US (3) US7879606B2 (ko)
EP (1) EP1381673B1 (ko)
JP (2) JP4499990B2 (ko)
KR (1) KR100947911B1 (ko)
CN (1) CN100362095C (ko)
AT (1) ATE431396T1 (ko)
CA (1) CA2441688C (ko)
DE (1) DE60232322D1 (ko)
ES (1) ES2328466T3 (ko)
HK (1) HK1063334A1 (ko)
MX (1) MXPA03008882A (ko)
NO (1) NO20034278L (ko)
NZ (1) NZ528462A (ko)
WO (1) WO2002077206A1 (ko)
ZA (1) ZA200307373B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79749C2 (en) 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
JP2006508662A (ja) 2002-12-04 2006-03-16 アプレラ コーポレイション ポリヌクレオチドの多重増幅
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
JP2007516706A (ja) * 2003-12-01 2007-06-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド 胎児肝臓細胞を含む組成物およびｈｃｖ感染で有用な方法
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2007098270A2 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same
BRPI0709567A2 (pt) 2006-03-16 2011-07-12 Vertex Pharma inibidores deuterados de protease de hepatite c
CA2679426A1 (en) 2007-02-27 2008-09-04 Luc Farmer Inhibitors of serine proteases
TW200846343A (en) 2007-02-27 2008-12-01 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
CL2008002549A1 (es) 2007-08-30 2010-09-03 Vertex Pharma Cocristal que comprende vx-950 y un formador de cocristal seleccionado de acido 3-metoxi-4hidroxibenzoico,acido 2,4-dihidroxibenzoico y acido 2,5-dihidroxibenzoico; metodo de preparacion; composicion farmaceutica que comprende el cocristal, util como agente antiviral en el tratamiento del hcv.
NZ585259A (en) 2007-12-04 2011-12-22 Prionics Ag Method for detecting bovine viral diarrhea virus (bvdv) in tissue samples using collagenase
CN101906487A (zh) * 2010-08-05 2010-12-08 中国兽医药品监察所 一种猪瘟病毒核酸标准物质的制备方法
ES2651414T3 (es) 2012-08-31 2018-01-26 The Governors Of The University Of Alberta Métodos para la producción de células que tienen un fenotipo de hepatocitos primarios humanos y composiciones
EP3289074B1 (en) * 2015-04-28 2023-10-04 Université de Strasbourg Clinical gene signature-based human cell culture model and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529920A (en) * 1988-12-14 1996-06-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human liver epithelial cell line and culture media therefor
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6069005A (en) 1991-08-07 2000-05-30 Albert Einstein College Of Medicine Of Yeshwa University Hapatoblasts and method of isolating same
EP1559778A1 (en) 1991-08-07 2005-08-03 Albert Einstein College Of Medicine Of Yeshiva University Proliferation of hepatocyte precursors
DE69434637T2 (de) 1993-11-19 2006-09-21 Albert Einstein College Of Medicine Of Yeshivauniversity, A Division Of Yeshiva Hepatoblasten und verfahren zu ihrer isolierung
KR19990036028A (ko) * 1995-08-01 1999-05-25 다니엘 케르니 일본뇌염 백신의 공업적인 생산방법 및 이에 의한 백신
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
BR9713368A (pt) * 1996-11-20 2001-09-18 Introgen Therapeutics Inc Processo melhorado para a produção e a purificação de vetores adenovirais
CA2217266A1 (en) * 1997-05-14 1998-11-14 The General Hospital Corporation Co-cultivation of cells in a micropatterned configuration
FR2775983B1 (fr) * 1998-03-13 2000-11-10 Pasteur Merieux Serums Vacc Milieu et procede de propagation et de multiplication virales
EP0972828A1 (en) 1998-06-24 2000-01-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Process for the in vitro replication of HCV
ATE414783T1 (de) 1998-12-07 2008-12-15 Univ Duke Verfahren zur isolierung von stammzellen
US20020182188A1 (en) 1999-01-19 2002-12-05 Reid Lola M. Human liver progenitors
US20020187133A1 (en) 1999-10-01 2002-12-12 Hiroshi Kubota Methods of isolating bipotent hepatic progenitor cells
HUP0203781A2 (hu) 2000-01-19 2003-03-28 University Of North Carolina At Chapel Hill Májszövet-forrás
CA2424781C (en) 2000-10-03 2018-11-06 University Of North Carolina At Chapel Hill Methods of isolating bipotent hepatic progenitor cells
AU2000277535B2 (en) 2000-10-03 2007-03-29 University Of North Carolina At Chapel Hill Processes for clonal growth of hepatic progenitor cells
EP1421222A4 (en) 2001-03-09 2004-07-07 Univ California CELL CULTURE SYSTEM FOR SYNTHESIS OF HEPATITIS C INFECTIOUS VIRUS
JP2006506966A (ja) * 2002-07-01 2006-03-02 ファルマシア・コーポレーション 血管新生において差次的に発現するｅｓｍ−１遺伝子、そのアンタゴニスト、および、それらを使用する方法

Also Published As

Publication number Publication date
US20020142449A1 (en) 2002-10-03
NO20034278D0 (no) 2003-09-25
US20130071834A1 (en) 2013-03-21
EP1381673A4 (en) 2004-11-10
CN100362095C (zh) 2008-01-16
CA2441688C (en) 2014-01-21
KR20040012739A (ko) 2004-02-11
ZA200307373B (en) 2005-06-29
ES2328466T3 (es) 2009-11-13
EP1381673B1 (en) 2009-05-13
CN1511190A (zh) 2004-07-07
CA2441688A1 (en) 2002-10-03
US20110229874A1 (en) 2011-09-22
JP2004529637A (ja) 2004-09-30
WO2002077206A1 (en) 2002-10-03
NZ528462A (en) 2005-11-25
EP1381673A1 (en) 2004-01-21
KR100947911B1 (ko) 2010-03-17
US8211696B2 (en) 2012-07-03
JP4499990B2 (ja) 2010-07-14
US7879606B2 (en) 2011-02-01
JP2010142249A (ja) 2010-07-01
DE60232322D1 (de) 2009-06-25
WO2002077206A9 (en) 2004-02-19
NO20034278L (no) 2003-11-25
MXPA03008882A (es) 2003-12-08
ATE431396T1 (de) 2009-05-15

Similar Documents

Publication Publication Date Title
HK1063334A1 (en) Compositions and methods useful for hcv infection
MY146518A (en) Methods to culture circovirus.
MX2020001944A (es) Poblaciones de celula madre de la placenta.
TW200611910A (en) Interferon-alpha polypeptides and conjugates
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
AU2002319780A1 (en) Alternative compositions and methods for the culture of stem cells
GB0127704D0 (en) Nucleic acid enrichment
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
WO2003105252A3 (en) CERAMIC ANODES AND PROCESS FOR PRODUCING THE SAME
WO2006116127A3 (en) Compositions for use in identification of bacteria
TW200619287A (en) Composition and method
TW200732349A (en) Anti-OX40L antibodies and methods using same
MX2007010045A (es) Pirazolopirimidinas.
EP1360314A4 (en) CHEMICALLY DEFINED MEDIUM FOR CULTIVATED MAMMALIAN CELLS
WO2010042551A3 (en) Methods for providing cellular lysates from cell wall-containing samples
SG148168A1 (en) Genetically modified microorganism and process for production of macrolide compound using the microorganism
MY162185A (en) Alumina particles and methods of making the same
TW200716130A (en) Purified form of tanaproget
DE60209795D1 (de) Zusammensetzungen enthaltend endgruppen-verkappte polyalkylenglykole
WO2002062970A8 (en) Enteric nervous system derived stem and progenitor cells and uses thereof
WO2004016743A3 (en) Culturing anaplasma
DE50105492D1 (de) Hefestamm zur prüfung der geno- und zytotoxizität komplexer umweltkontaminationen
GR1004526B (el) Μεθοδος απομονωσης και παραγωγης της πρωτεινης dnase χρησιμοποιωντας ως πρωτη υλη το συμπλοκο ζυμωτικο σκευασμα "collagenolytic proteinase", το οποιο παραγεται απο το ηπατοπαγκρεας των καβουριων της καμτσατκας (paralithodes camtschatica)
GB2442906A (en) 2, 4-Pentanedione disulfonate salts, methods for their preparation and their use in cement compositions
TW200706651A (en) Placental stem cell and methods thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150327